circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X Cytokinetics, Inc. Annual Shareholder Meeting
    May 15, 2019 10:30 AM PDT

    Cytokinetics, Inc. Annual Shareholder Meeting
    May 15, 2019 10:30 AM PDT
  • Webcast
    X Q1 2019 Cytokinetics, Inc. Earnings Conference Call
    May 9, 2019 4:30 PM EDT

    Q1 2019 Cytokinetics, Inc. Earnings Conference Call
    May 9, 2019 4:30 PM EDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Reports First Quarter 2019 Financial Results
GALACTIC-HF Continues Following Interim Analysis for Futility;  METEORIC-HF Opened to Enrollment Phase 1 Data for CK-274 Expected in Q3 2019; Planning Underway for Potential Progression to Phase 2 FORTITUDE-ALS Demonstrates Patients on All Doses of Reldesemtiv Declined Less Than Patients on Placebo
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 15, 2019 at 10:30 AM Pacific Time at the Embassy Suites Hotel , located at 250 Gateway Boulevard in South
Toggle Summary Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting
Trial Did Not Meet Statistical Significance for Primary Efficacy Analysis Change from Baseline in Percent Predicted SVC at Week 12 SVC Change from Baseline (All Active vs Placebo) ALSFRS-R Change from Baseline (All Active vs Placebo) Change from Baseline in ALSFRS-R Gross Motor Domain Patients on
Toggle Summary Cytokinetics to Announce First Quarter Results on May 9, 2019
SOUTH SAN FRANCISCO, Calif. , April 25, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report first quarter results on May 9, 2019 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a conference

EVENTS

There are currently no events to display.